Global

‡ In these countries please contact our distributor

Las nuevas guías de la OMS recomiendan el uso de TPN para ayudar a reducir el riesgo de infección del sitio quirúrgico

22 Noviembre 2016

Smith & Nephew (LSE:SN, NYSE:SNN), la empresa mundial de tecnología médica, acoge con gran satisfacción la publicación de las nuevas directrices mundiales de la Organización Mundial de la Salud (OMS) que delinean estrategias para reducir las tasas de infección del sitio quirúrgico (ISQ).1 

Entre los 27 temas tratados, las directrices recomiendan el uso (profiláctico) de la Terapia de Presión Negativa en pacientes adultos en el cierre de incisiones quirúrgicas de alto riesgo. Las directrices de la OMS también apuntan hacia la adopción de dispositivos portátiles para asegurar que el uso de la TPN no prolonga la estancia hospitalaria.

PICO

PICO™ es un sistema único de TPN de un solo uso y su papel en la reducción de las complicaciones del sitio quirúrgico se documenta en un reciente meta-análisis2. Through a wealth of clinical evidence,  A través de una gran cantidad de evidencia clínica, PICO™ se está convirtiendo rápidamente en la primera elección en el uso de TPN y se ha demostrado la capacidad de manejar una amplia gama de heridas con riesgo de complicaciones, tanto de manera clínica como económica.2 3 4 5 Desde que la OMS revisó la evidencia de TPN (octubre 2015) se ha publicado un nuevo ECA (ensayo controlado aleatorio) que demuestra la capacidad de PICO para reducir las complicaciones del sitio quirúrgico en la cirugía ortopédica. 6  Recientemente un estudio aleatorizado adicional en cirugía cardiotorácica también mostró reducciones en ISQ para los pacientes tratados con PICO.

El Dr. Niz Islam, Vicepresidente de Asuntos Científicos y Médicos de Smith & Nephew, dijo: “Estas nuevas guías de la OMS proporcionan importantes ideas sobre optimización de las estrategias de manejo clínico para la prevención de ISQ que son una preocupación creciente para los proveedores de salud y sus pacientes en todo el mundo. Esta es una suma significativa al creciente cuerpo de literatura que respalda la TPN como una opción de tratamiento profiláctico efectivo para ISQ. Esto sigue con la reciente publicación del Documento de Consenso de la World Union of Wound Healing Societies (WUWHS) sobre el rol de la TPN en el manejo del cierre de las incisiones quirúrgicas".

El documento de Consenso de la WUWHS fue publicado en Septiembre de 2016 y respaldado por una beca educativa de Smith & Nephew.
Puede descargase el documento de consenso en el siguiente enlace: http://www.wuwhs2016.com/files/WUWHS_SI_consensus_Web.pdf.

Enquiries

Media

David Snyder
Smith & Nephew
+1 (978)-749-1440

Investor/Analyst  

Ingeborg Oie
Smith & Nephew
+44 (0)20 7401 7646

About Smith & Nephew

Smith & Nephew is a global medical technology business dedicated to helping healthcare professionals improve people's lives. With leadership positions in Orthopaedic Reconstruction, Advanced Wound Management, Sports Medicine and Trauma & Extremities, Smith & Nephew has around 15,000 employees and a presence in more than 100 countries. Annual sales in 2015 were more than $4.6 billion. Smith & Nephew is a member of the FTSE100 (LSE:SN, NYSE:SNN).

For more information about Smith & Nephew, please visit our website www.smith-nephew.com, follow @SmithNephewplc on Twitter or visit SmithNephewplc on Facebook.com.

To learn more about what we do to help reduce surgical site complications, please visit www.closertozero.com

Forward-looking Statements

This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith & Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith & Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith & Nephew are qualified by this caution. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith & Nephew's expectations.

Trademark of Smith & Nephew.  Certain marks registered US Patent and Trademark Office.

References

1. WHO. Global Guidelines for the Prevention of Surgical Site Infection. Geneva; 2016 http://www.who.int/gpsc/ssi-prevention-guidelines/en/

2. Hyldig N, Birke-Sorensen H, Kruse M, et al. Meta-analysis of negative-pressure wound therapy for closed surgical incisions. Br J Surg. 2016;103(5):477-486. doi:10.1002/bjs.10084.

3. Adogwa O, Fatemi P, Perez E, et al. Negative pressure wound therapy reduces incidence of postoperative wound infection and dehiscence after long-segment thoracolumbar spinal fusion: a single institutional experience. Spine J. 2014;14(12):2911-2917. doi:10.1016/j.spinee.2014.04.011.

4. Matsumoto T, Parekh SG. Use of Negative Pressure Wound Therapy on Closed Surgical Incision After Total Ankle Arthroplasty. Foot ankle Int. 2015;36(7):787-794. doi:10.1177/1071100715574934.

5. Nherera L. Cost-effectiveness of single use negative pressure wound therapy system (sNPWT*) to reduce surgical site complications (SSC) in routine primary hip and knee replacements. SAWC Fall. 2016;(Poster).

6. Karlakki SL, Hamad AK, Whittal C, Graham NM, Banerjee RD, Kuiper JH. Incisional negative pressure wound therapy dressings (iNPWT)in routine primary hip and knee arthroplasties: A randomised controlled trial. Bone Joint Res. 2016;5(8):328-337. doi:10.1302/2046-3758.58.BJR- 2016-0022.R1

7. Witt-Majchrzak A, Żelazny P, Snarska J. Preliminary outcome of treatment of postoperative primarily closed sternotomy wounds treated using negative pressure wound therapy. Pol Przegl Chir. 2015;86(10):456-465. doi:10.2478/pjs-2014-0082.

Note: Some of the studies referenced above used PICO Soft Port, which is not cleared for use in the USA.

PICO

Dispositivo ultrapotátil de Terapia de Presión Negativa

Pulsa